Skip to main content

Table 3 Reported sample characteristics for each measure.

From: Measuring the psychosocial health of adolescent and young adult (AYA) cancer survivors: a critical review

  Sample characteristics
Measure Inclusion/exclusion Setting Response rate (%) Sample
size (n)
Age
(yrs)
Gender (%) Cancer type
(%)
Cancer treatment stage (%)
AQoL [35] Reported Hematology
/oncology clinic
95 75 9-20
mean 12.4
M (55)
F (45)
Leukaemia (50)
Bone/joint (17)
Lymphomas (9)
Neurological (9)
Hodgkin's (5)
Other (9)
In treatment (55)
Pre or post treatment (45)
MMQL Adolescent Forrm [52] - Nine hospitals - 268 13-20.9
median 16.6
M (56)
F (44)
Leukaemia ALL (37)
Leukaemia AML (8)
Hodgkin's (11)
Non-Hodgkin's (11)
Brain (6)
Other (27)
On therapy (41)
Off therapy > 1 year (59)
PedsQL 3.0 Cancer Module (C&A) [55] Reported Hematology/oncology center and Center for Cancer and Blood Diseases - 220 5-18
mean 10.9
M (56)
F (44)
Leukaemia (50)
Brain (7)
Non-Hodgkin's (6)
Hodgkin's (3)
Wilm's Tumor (6)
Other (28)
On treatment (54)
Off treatment < 1 year (18)
Off treatment > 1 year (28)
QOL-CS [16] Reported University medical center 53 176 16-28
mean 21.8
M (43)
F (57)
Leukaemia (30)
Brain/CNS (11)
Lymphoma (21)
Wilm's Tumor (10)
Sarcomas (16)
Other (11)
3-27 yrs post-diagnosis (100)
(average 13.3 yrs)
PCQL-32 [59] Reported Three pediatric cancer centers 89.5 291 8-18
mean 11.78
M (61)
F (39)
Leukaemia ALL (44)
Leukaemia AML (6)
Leukaemia other (1)
Hodgkin's (6)
Non-Hodgkin's (9)
Other (34)
Newly on-treatment (37)
Relapsed on treatment (8)
Remission off-treatment (11)
Long-term off-treatment (44)
PCQL Modular Approach [62] Reported Three pediatric cancer centers 89.5 291 8-18
mean 11.78
- - On treatment (45)
Off treatment (55)
PIE [63] Reported Children's cancer unit - 41 8-24
mean
14.6
M (49)
F (51)
Leukaemia ALL (68)
Wilm's Tumor (15)
Sarcomas (12)
Non-Hodgkin's (5)
Maintenance treatment (41)
Follow-up only (59)
  1. *Data taken from the publication referenced in the Measure column unless otherwise referenced within the table.